In addition, the anti-tumor efficacy of anti-Dll4 and anti-VEGF combination therapy was also observed in a sunitinib resistant ccRCC model, which further highlights the great therapeutic potential of targeting these two pathways. This evidence concerns the gene DLL4 and nonpapillary renal cell carcinoma.